Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188795 | 0.76 | PNMT (0.49) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL15391010 | 0.75 | PNMT (0.47) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL3913019 | 0.75 | PNMT (0.47) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL7952419 | 0.75 | PNMT (0.47) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL10959497 | 0.75 | TRPA1 (0.52) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL11824304 | 0.72 | PNMT (0.45) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL11156832 | 0.71 | ACP3 (0.44) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL9586210 | 0.71 | PNMT (0.44) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL958288 | 0.71 | PNMT (0.47) | PNMTIDO1TDO2ACP3CES2 | |
| SCHEMBL11075354 | 0.71 | IDO1 (0.45) | PNMTIDO1TDO2ACP3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0674624-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013643-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | PNMT 1842/4885IDO1 2553/4885TDO2 3357/4885 |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | PNMT 1842/4885IDO1 2553/4885TDO2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.